Literature DB >> 11072600

Psychological well-being in patients with primary Sjögren's syndrome.

S T Valtýsdóttir1, B Gudbjörnsson, R Hällgren, J Hetta.   

Abstract

OBJECTIVES: To evaluate quality of life and psychological symptoms in patients with primary Sjögren's syndrome and to compare this with patients with rheumatoid arthritis.
METHODS: A standardised questionnaire, the Psychological General Well-Being Index (PGWB), was used to examine the quality of life and psychological symptoms in patients with primary Sjögren's syndrome (pSS; n = 34). Patients with rheumatoid arthritis (RA; n = 32) were used as patient controls.
RESULTS: The total mean score +/- SD for PGWB was 84.9 +/- 16.2 in pSS patients and significantly lower (p = 0.001) than in RA patients (97.7 +/- 17.5). Patients with pSS had an increased propensity for depressed mood (p = 0.0009), and suffered from reduced well-being (p = 0.002) and impaired vitality (p = 0.003).
CONCLUSION: The results suggest that patients with pSS have a reduced quality of life, a higher degree of distress and a lower sense of well-being than patients with RA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072600

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

1.  Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.

Authors:  J M van Woerkom; A A Kruize; R Geenen; E N van Roon; R Goldschmeding; S M M Verstappen; J A G van Roon; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

2.  Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Konstantinos Kotsis; Paraskevi V Voulgari; Niki Tsifetaki; Alexandros A Drosos; André F Carvalho; Thomas Hyphantis
Journal:  Rheumatol Int       Date:  2014-04-27       Impact factor: 2.631

3.  Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Authors:  Lynn C Epstein; Gina Masse; Jerold S Harmatz; Tammy M Scott; Athena S Papas; David J Greenblatt
Journal:  Clin Rheumatol       Date:  2013-12-15       Impact factor: 2.980

4.  [Sjögren's syndrome. Current aspects from a rheumatological point of view].

Authors:  C Tomiak; T Dörner
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

5.  Mental wellbeing and quality of sexual life in women with primary Sjögren's syndrome are related to circulating dehydroepiandrosterone sulphate.

Authors:  S Th Valtysdottir; L Wide; R Hallgren
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

6.  Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States.

Authors:  Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
Journal:  Health Qual Life Outcomes       Date:  2009-05-27       Impact factor: 3.186

7.  Psychiatric manifestations of autoimmune disorders.

Authors:  David B Weiss; Jarl Dyrud; Robert M House; Thomas P Beresford
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.972

8.  Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye.

Authors:  Susan Vitale; Linda A Goodman; George F Reed; Janine A Smith
Journal:  Health Qual Life Outcomes       Date:  2004-09-01       Impact factor: 3.186

9.  Vision-related quality of life and psychological status in Chinese women with Sjogren's syndrome dry eye: a case-control study.

Authors:  Yuqiu Zhang; Tong Lin; Alice Jiang; Naiqing Zhao; Lan Gong
Journal:  BMC Womens Health       Date:  2016-12-12       Impact factor: 2.809

10.  The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.

Authors:  Abdel-Aziz Shaheen; Gilaad G Kaplan; Wagdi Almishri; Isabelle Vallerand; Alexandra D Frolkis; Scott Patten; Mark G Swain
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.